Article Text

Download PDFPDF
Management of Crohn’s stricture: medical, endoscopic and surgical therapies
  1. Mohamed Saleh Ismail1,
  2. Aline Charabaty2
  1. 1Gastroenterology and Hepatology, The University of Alabama at Birmingham, Birmingham, Alabama, USA
  2. 2Division of Gastroenterology and Hepatology, Johns Hopkins University, Sibley Memorial Hospital, Washington, District of Columbia, USA
  1. Correspondence to Dr Aline Charabaty, Division of Gastroenterology, Johns Hopkins Medicine, Washington, District of Columbia, USA; acharab1{at}


Patients with Crohn’s disease are at high risk of presenting with or developing a bowel stricture during the course of their disease. The available therapeutic options to manage a symptomatic Crohn’s stricture include medical therapy (mainly biologics), surgical resection and endoscopic interventions. The choice of therapeutic modality depends on the clinical presentation of the stricture, the nature of the stricture (inflammatory vs fibrotic, primary vs anastomotic) and its anatomical characteristics on endoscopy and imaging (length, number, location of strictures and severity of obstruction). The aim herein is to provide an overview of the comprehensive assessment of a Crohn’s stricture and to review the indications of the different therapeutic modalities, their success rates and their limitations to help clinicians properly evaluate and manage Crohn’s strictures.

  • Crohn's disease
  • endoscopic procedures
  • IBD clinical

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors MSI and AC reviewed the literature, drafted the manuscript and approved the final version. AC is the article guarantor.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests AC: consulting and/or advisory board for Pfizer, Janssen, Takeda, AbbVie and BMS.

  • Provenance and peer review Commissioned; externally peer reviewed.